Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes.
BIOMECHANICS
BONE μCT
DIABETES
OSTEOBLASTS
SCLEROSTIN
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
15
04
2020
revised:
21
07
2020
accepted:
02
08
2020
pubmed:
11
8
2020
medline:
29
7
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
Increased circulating sclerostin and accumulation of advanced glycation end-products (AGEs) are two potential mechanisms underlying low bone turnover and increased fracture risk in type 2 diabetes (T2D). Whether the expression of the sclerostin-encoding SOST gene is altered in T2D, and whether it is associated with AGEs accumulation or regulation of other bone formation-related genes is unknown. We hypothesized that AGEs accumulate and SOST gene expression is upregulated in bones from subjects with T2D, leading to downregulation of bone forming genes (RUNX2 and osteocalcin) and impaired bone microarchitecture and strength. We obtained bone tissue from femoral heads of 19 T2D postmenopausal women (mean glycated hemoglobin [HbA1c] 6.5%) and 73 age- and BMI-comparable nondiabetic women undergoing hip replacement surgery. Despite similar bone mineral density (BMD) and biomechanical properties, we found a significantly higher SOST (p = .006) and a parallel lower RUNX2 (p = .025) expression in T2D compared with non-diabetic subjects. Osteocalcin gene expression did not differ between T2D and non-diabetic subjects, as well as circulating osteocalcin and sclerostin levels. We found a 1.5-fold increase in total bone AGEs content in T2D compared with non-diabetic women (364.8 ± 78.2 versus 209.9 ± 34.4 μg quinine/g collagen, respectively; p < .001). AGEs bone content correlated with worse bone microarchitecture, including lower volumetric BMD (r = -0.633; p = .02), BV/TV (r = -0.59; p = .033) and increased trabecular separation/spacing (r = 0.624; p = .023). In conclusion, our data show that even in patients with good glycemic control, T2D affects the expression of genes controlling bone formation (SOST and RUNX2). We also found that accumulation of AGEs is associated with impaired bone microarchitecture. We provide novel insights that may help understand the mechanisms underlying bone fragility in T2D. © 2020 American Society for Bone and Mineral Research (ASBMR).
Identifiants
pubmed: 32777114
doi: 10.1002/jbmr.4153
pmc: PMC8143610
mid: NIHMS1702959
doi:
Substances chimiques
Glycated Hemoglobin A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2415-2422Subventions
Organisme : NIAMS NIH HHS
ID : K01 AR069116
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR074992
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR074441
Pays : United States
Informations de copyright
© 2020 American Society for Bone and Mineral Research (ASBMR).
Références
Bone. 2016 Jan;82:69-78
pubmed: 25722065
J Clin Endocrinol Metab. 2016 Jun;101(6):2502-10
pubmed: 27115060
Nat Rev Endocrinol. 2017 Apr;13(4):208-219
pubmed: 27658727
J Biomech. 2007;40(11):2426-33
pubmed: 17257604
Eur J Endocrinol. 2017 Mar;176(3):R137-R157
pubmed: 28049653
Calcif Tissue Int. 2017 Apr;100(4):402-411
pubmed: 28229177
Bone. 2017 Mar;96:45-50
pubmed: 27888056
J Bone Miner Res. 2000 Jan;15(1):32-40
pubmed: 10646112
Cold Spring Harb Protoc. 2010 Jun;2010(6):pdb.prot5439
pubmed: 20516177
Bone. 2016 Jan;82:28-34
pubmed: 26211989
Genes Immun. 2005 Jun;6(4):279-84
pubmed: 15815687
Ann N Y Acad Sci. 2017 Aug;1402(1):18-30
pubmed: 28926113
N Engl J Med. 2016 Jan 21;374(3):254-62
pubmed: 26789873
Osteoporos Int. 2014 Jun;25(6):1697-708
pubmed: 24676844
Bone. 2019 May;122:22-30
pubmed: 30735798
Stem Cells Dev. 2015 May 15;24(10):1150-63
pubmed: 25603196
Bone. 2018 Nov;116:58-66
pubmed: 30021126
J Clin Endocrinol Metab. 2014 Dec;99(12):E2584-90
pubmed: 25144629
BMC Musculoskelet Disord. 2016 Aug 31;17:377
pubmed: 27582133
Bone Rep. 2018 Mar 03;8:90-94
pubmed: 29955626
Crit Rev Eukaryot Gene Expr. 2009;19(3):171-80
pubmed: 19883363
J Clin Endocrinol Metab. 2012 Sep;97(9):3240-50
pubmed: 22740707
Int J Endocrinol. 2016;2016:1615735
pubmed: 28044077
Bone. 2016 Feb;83:149-155
pubmed: 26555635
Bone Res. 2016 Mar 22;4:16001
pubmed: 27019762
Nat Protoc. 2006;1(3):1559-82
pubmed: 17406449
Diabetes. 2017 Jun;66(6):1432-1442
pubmed: 28533294
Diabetes Care. 2015 Jan;38 Suppl:S8-S16
pubmed: 25537714
J Bone Miner Res. 2018 Jan;33(1):63-69
pubmed: 28861910
Bonekey Rep. 2016 Aug 24;5:829
pubmed: 27579166
Osteoporos Int. 2018 Dec;29(12):2585-2596
pubmed: 30066131
Int J Legal Med. 2012 Nov;126(6):943-52
pubmed: 23010907
J Bone Miner Res. 2019 Jul;34(7):1191-1206
pubmed: 30866111
World J Diabetes. 2019 Aug 15;10(8):421-445
pubmed: 31523379
J Bone Miner Res. 2018 Jan;33(1):54-62
pubmed: 28929525
Bone. 2018 Sep;114:32-39
pubmed: 29857063
J Bone Miner Res. 2010 Feb;25(2):285-91
pubmed: 19594301
J Bone Miner Res. 2015 Dec;30(12):2207-14
pubmed: 26060094
Bone. 2007 Apr;40(4):1144-51
pubmed: 17257914
Bone. 2017 Mar;96:29-37
pubmed: 27742498
Acta Diabetol. 2018 Apr;55(4):305-314
pubmed: 29333578